Loading...
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...
Na minha lista:
| Udgivet i: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6591141/ https://ncbi.nlm.nih.gov/pubmed/30821848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13283 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|